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WnT proteins are a large family of secreted glycopro-
teins activating the WnT-pathway. WnT binding to Friz-
zled (Fz) results in the activation of Dishevelled (Dsh), 
which inhibits the activity of gSK3-b, resulting in de-
phosphorylation and stabilization of b-catenin, enabling 
it to accumulate within the nucleus, where it interacts with 
members of the T-cell factor/lymphocyte enhancer factor 
(TCF/lEF) family of trans-cription factors to stimulate 
the expression of target genes. in summary, the canonical 
pathway translates a WnT signal into the transient tran-
scription of a TCF/lEF target gene programme. nuclear 
b-catenin then interacts with various transcription factors 
to cause cellular proliferation and differentiation. There 
are several WnT-antagonists that may be classified in two 
types: a) those that interfere with WnT activity by bind-
ing  to  low-density  lipoprotein  receptor-related  proteins 
(lrP-5  or  lrP-6),  including  Sclerostin  and  Dickkopf 
(DKK) proteins, and b) those that interact directly with 
WnT proteins, including WiF-1. Although the role of the 
WnT pathway in nasopharyngeal carcinoma (nPC) has 
not been fully explored, there is abundant evidence that 
aberrant WnT signalling is involved in its development 1 2. 
Very little data is available on this pathway in laryngeal 
squamous cell carcinoma (lSCC) 3-5. Cytoplasmic b-cat-
enin plays a major role in the normal cell by binding to 
the intracellular domain of E-cadherin to maintain cell-
cell  adhesion.  The  expression  of  E-cadherin  has  been 
found to be down-regulated in many cancers including 
nasopharyngeal carcinoma 2 3. it has been suggested that 
E-cadherin down-regulation may play a role in tumour 
progression and metastasis. Strong b-catenin expression 
is significantly associated with invasion and metastasis of 
carcinomas of the head and neck, oesophagus, stomach, 
colon, liver, lung, breast, female genitalia, prostate, blad-
der and pancreas, as well as melanoma. recently, several 
studies have pointed to the considerable involvement of 
b-catenin, not only in malignant transformation, but also 
in the regulation of physiological functions, and expres-
sion of this adhesion molecule in human nasopharyngeal 
carcinoma has been investigated 6 7; however, it has not yet 
been thoroughly explored in lSCC.
We sought to evaluate the expression of WnT pathway ac-
tivators (Wnt-1, Wnt-5a) and inhibitors (WiF-1 and Dkk-1) 
in tissues from patients with lSCC and nPC and, for pur-
poses of comparison, in patients with non-tumour patholo-
gies. Expression was determined by immunohistochemi-
cal analysis using paraffin-embedded specimens from 16 
lSCC patients (12 men, 4 women; age 46-72), 18 nPC 
patients (11 men, 7 women; age 44-78); 11 non-neoplastic 
nodule specimens (6 men, 5 women; age 19-97) were as-
sayed for control purposes. immunohistochemistry (ihC) 
was performed using the peroxidase-antiperoxidase tech-
nique. Staining for Wnt-1 (1:100), Wnt-5a (1:200), WiF-1 
(1:200) and Dkk-1 (1:250) from Abcam (Abcam, Cam-
bridge, UK) was studied on nPC and lSCC tissues. histo-
logical evaluation was performed by two pathologists, who 
independently scored the results of immunohistochemical 
staining; any discrepant scores were re-examined to arrive 
at a consensus score. human breast tumour was used as 
positive control, and negative controls were obtained by re-
placing the primary antibodies with PBS.
Surprisingly, none of the tissues tested (tumour tissues 
regardless of location, and non-tumour tissues) exhib-
ited immunoexpression of the WnT pathway activators 
Wnt-1 and Wnt-5a, whereas all tissues stained positive 
for the pathway inhibitors, WiF-1 and Dkk-1, displaying 
similar levels of expression. These findings would sug-
gest that the WnT pathway is inactive in these types of 
tumours. Earlier research failed to detect nuclear b-cat-
enin, suggesting that the canonical WnT pathway may 
be inactivatedin both nPC 8 and lSCC (data not shown). 
however, this cannot be categorically confirmed, since 
stabilized b-catenin was detected in the cytoplasm. goi-
liomus et al., in a study of 97 lSCCs, detected nuclear b-WnT pathway in laryngeal squamous cell carcinoma and nasopharyngeal carcinoma
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catenin in some samples 9, perhaps due to differences in 
tissue processing or to the immunohistochemical stain-
ing method used.
Although this hypothesis appears to be confirmed by the 
present findings, further research is required to determine 
whether the WnT pathway is activated by overexpression 
of its receptors or by the silencing of its suppressors. A 
Western blot could be used for this purpose, with a view 
to measuring possible alterations in protein levels in fresh 
tissue, and to investigate the possible activation of the non-
canonical WnT pathway that includes signalling through 
calcium flux, JnK and heterotrimeric g proteins.
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